Logo image of ELABS.OL

ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

OSL:ELABS - Euronext Oslo - NO0010722283 - Common Stock - Currency: NOK

9.32  +0.16 (+1.75%)

Fundamental Rating

3

Taking everything into account, ELABS scores 3 out of 10 in our fundamental rating. ELABS was compared to 95 industry peers in the Software industry. While ELABS seems to be doing ok healthwise, there are quite some concerns on its profitability. ELABS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ELABS had positive earnings in the past year.
In the past year ELABS has reported a negative cash flow from operations.
In the past 5 years ELABS always reported negative net income.
In the past 5 years ELABS always reported negative operating cash flow.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ELABS's Return On Assets of -6.37% is on the low side compared to the rest of the industry. ELABS is outperformed by 66.32% of its industry peers.
ELABS has a worse Return On Equity (-7.05%) than 61.05% of its industry peers.
Industry RankSector Rank
ROA -6.37%
ROE -7.05%
ROIC N/A
ROA(3y)-7.78%
ROA(5y)-7.71%
ROE(3y)-8.59%
ROE(5y)-9.8%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

ELABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

ELABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ELABS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ELABS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ELABS's Debt to Equity ratio of 0.04 is amongst the best of the industry. ELABS outperforms 82.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.71%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

ELABS has a Current Ratio of 8.41. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
ELABS has a better Current ratio (8.41) than 96.84% of its industry peers.
ELABS has a Quick Ratio of 8.41. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 8.41, ELABS belongs to the best of the industry, outperforming 96.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.41
Quick Ratio 8.41
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

ELABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 122.22%, which is quite impressive.
EPS 1Y (TTM)122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%400.64%

3.2 Future

Based on estimates for the next years, ELABS will show a very strong growth in Earnings Per Share. The EPS will grow by 195.30% on average per year.
The Revenue is expected to grow by 62.13% on average over the next years. This is a very strong growth
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A

3.3 Evolution

ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ELABS is valuated quite expensively with a Price/Earnings ratio of 116.50.
ELABS's Price/Earnings is on the same level as the industry average.
ELABS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.78.
With a Price/Forward Earnings ratio of 12.93, ELABS is valued correctly.
91.58% of the companies in the same industry are more expensive than ELABS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.32. ELABS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 116.5
Fwd PE 12.93
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ELABS's earnings are expected to grow with 195.30% in the coming years.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y309.11%
EPS Next 3Y195.3%

More info and screens

0

5. Dividend

5.1 Amount

ELABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELLIPTIC LABORATORIES ASA

OSL:ELABS (4/25/2025, 7:00:00 PM)

9.32

+0.16 (+1.75%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)N/A N/A
Inst Owners35.91%
Inst Owner ChangeN/A
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap981.12M
Analysts84.44
Price Target19.38 (107.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.25%
Min Revenue beat(2)-19.76%
Max Revenue beat(2)-12.73%
Revenue beat(4)0
Avg Revenue beat(4)-29.61%
Min Revenue beat(4)-79.79%
Max Revenue beat(4)-6.15%
Revenue beat(8)1
Avg Revenue beat(8)-27.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 116.5
Fwd PE 12.93
P/S 10.49
P/FCF N/A
P/OCF N/A
P/B 3.12
P/tB 3.98
EV/EBITDA N/A
EPS(TTM)0.08
EY0.86%
EPS(NY)0.72
Fwd EY7.74%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.89
BVpS2.99
TBVpS2.34
PEG (NY)0.15
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.37%
ROE -7.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.78%
ROA(5y)-7.71%
ROE(3y)-8.59%
ROE(5y)-9.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.16%
Cap/Sales 32.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.41
Quick Ratio 8.41
Altman-Z N/A
F-Score4
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)191.96%
Cap/Depr(5y)213.4%
Cap/Sales(3y)38.18%
Cap/Sales(5y)37.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.63%
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%400.64%
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A
EBIT growth 1Y32.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year238.57%
EBIT Next 3Y159.98%
EBIT Next 5Y124.72%
FCF growth 1Y-304.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-405.01%
OCF growth 3YN/A
OCF growth 5YN/A